- Tradename: Tecentriq® (Genentech).
- Main target: PD-L1.
- Cancer: Urothelial carcinoma, the most common type of bladder cancer.
- Patient: Patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment. 106 more words
Tags » Bladder
Monday’s…. What is better than a Monday? How about an early Urodynamics procedure, that someone has been fretting about since April….
Bright and early we arrive, only to wait, which makes it that much harder when you just want to get it done and over with. 428 more words